NCT05656248View on ClinicalTrials.gov

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

August 28, 2025

Study Completion Date

August 31, 2028

Conditions

Myeloid Neoplasm

Interventions

DRUG

CPX-351

Given Intraveneously (IV)

DRUG

MHA

Given Intrathecal (IT)

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo HSCT

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors

Collaborators (1)

Jazz Pharmaceuticals

All Listed Sponsors

collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER